• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau Hyderabad, Jan. 21 Dr Reddy’s Laboratories Ltd has entered into a pact with Novartis Pharma AG to settle a legal battle pertaining to a generic version of Rivastigmine tartrate capsules sold under the trade-name Exelon.

“Under the terms of the agreement, Dr Reddy’s will not launch its generic Rivastigmine tartrate capsules until sometime before the expiry of the Orange Book patents claiming Rivastigmine,” Dr Reddy’s said in a release.

The patent for Rivastigmine would expire in August 2012.

The agreement also stipulated a dismissal of the lawsuits in the US relating to the Abbreviated New Drug Applications (ANDA) filed by Dr Reddy’s for a generic version of Rivastigmine tartrate.

More Stories on : Pharmaceuticals | Corporate Disputes | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Wheat acreage deficit narrows down to 6 lakh hectares

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line